321
Views
115
CrossRef citations to date
0
Altmetric
Review

Role of the aryl hydrocarbon receptor in drug metabolism

, &
Pages 9-21 | Published online: 14 Jun 2005

Bibliography

  • BJELDANES LF, KIM JY, GROSE KR, BARTHOLOMEW JC, BRADFIELD CA: Aromatic hydrocarbon responsivenessreceptor agonists generated from indole-3- carbinol in vitro and in vivo: comparisons with 2,3,7,8-tetrachlorodibenzo-p-dioxin. Proc. Natl Acad. Sci. USA (1991) 88:9543–9547.
  • DENISON MS, NAGY SR: Activation of the aryl hydrocarbon receptor by structurally diverse exogenous and endogenous chemicals. Ann. Rev. Pharmacol. Toxicol. (2003) 43:309–334.
  • ADACHI J, MORI Y, MATSUI S et al.: Indirubin and indigo are potent aryl hydrocarbon receptor ligands present in human urine. J. Biol. Chem. (2001) 276:31475–31478.
  • PETER GUENGERICH F, MARTIN MV, MCCORMICK WA, NGUYEN LP, GLOVER E, BRADFIELD CA: Aryl hydrocarbon receptor response to indigoids in vitro and in vivo. Arch. Biochem. Biophys. (2004) 423:309–316.
  • SUGIHARA K, KITAMURA S, YAMADA T et al.: Aryl hydrocarbon receptor-mediated induction of microsomal drug-metabolizing enzyme activity by indirubin and indigo. Biochem. Biophys. Res. Commun. (2004) 318:571–578.
  • BITTINGER MA, NGUYEN LP, BRADFIELD CA: Aspartate aminotransferase generates proagonists of the aryl hydrocarbon receptor. Mol. Pharmacol. (2003) 64:550–556.
  • SONG J, CLAGETT-DAME M, PETERSON RE et al.: A ligand for the aryl hydrocarbon receptor isolated from lung. Proc. Natl Acad. Sci. USA (2002) 99:14694–14699.
  • LAHVIS GP, LINDELL SL, THOMAS RS et al.: Portosystemic shunting and persistent fetal vascular structures in aryl hydrocarbon receptor-deficient mice. Proc. Natl. Acad. Sci. USA (2000) 97:10442–10447.
  • LIN TM, KO K, MOORE RW, BUCHANAN DL, COOKE PS, PETERSON RE: Role of the aryl hydrocarbon receptor in the development of control and 2,3,7,8-tetrachlorodibenzo-pdioxin- exposed male mice. J. Toxicol. Environ. Health A (2001) 64:327–342.
  • SCHMIDT JV, SU GH, REDDY JK, SIMON MC, BRADFIELD CA: Characterization of a murine Ahr null allele: involvement of the Ah receptor in hepatic growth and development. Proc. Natl Acad. Sci. USA (1996) 93:6731–6736.
  • FERNANDEZ-SALGUERO P, PINEAU T, HILBERT DM et al. : Immune system impairment and hepatic fibrosis in mice lacking the dioxin-binding Ah receptor. Science (1995) 268:722–726.
  • VORDERSTRASSE BA, STEPPAN LB, SILVERSTONE AE, KERKVLIET NI: Aryl hydrocarbon receptor-deficient mice generate normal immune responses to model antigens and are resistant to TCDDinduced immune suppression. Toxicol. Appl. Pharmacol. (2001) 171:157–164.
  • MIMURA J, YAMASHITA K, NAKAMURA K et al.: Loss of teratogenic response to 2,3,7,8-tetrachlorodibenzo-pdioxin (TCDD) in mice lacking the Ah (dioxin) receptor. Genes Cells (1997) 2:645–654.
  • SHIMIZU Y, NAKATSURU Y, ICHINOSE M et al.: Benzo[a]pyrene carcinogenicity is lost in mice lacking the aryl hydrocarbon receptor. Proc. Natl Acad. Sci. USA (2000) 97:779–782.
  • HUFF JE, MOORE JA, SARACCI R, TOMATIS L: Long-term hazards of polychlorinated dibenzodioxins and polychlorinated dibenzofurans. Environ. Health Perspect. (1980) 36:221–240.
  • PETRULIS JR, PERDEW GH: The role of chaperone proteins in the aryl hydrocarbon receptor core complex. Chem. Biol. Interact. (2002) 141:25–40.
  • IKUTA T, EGUCHI H, TACHIBANA T, YONEDA Y, KAWAJIRI K: Nuclear localization and export signals of the human aryl hydrocarbon receptor. J. Biol. Chem. (1998) 273:2895–2904.
  • IKUTA T, TACHIBANA T, WATANABE J, YOSHIDA M, YONEDA Y, KAWAJIRI K: Nucleocytoplasmic shuttling of the aryl hydrocarbon receptor. J. Biochem. (2000) 127:503–509.
  • PETRULIS JR, HORD NG, PERDEWGH: Subcellular localization of the aryl hydrocarbon receptor is modulated by the immunophilin homolog hepatitis B virus X-associated protein 2. J. Biol. Chem. (2000) 275:37448–37453.
  • POLLENZ RS, BARBOUR ER: Analysis of the complex relationship between nuclear export and aryl hydrocarbon receptormediated gene regulation. Mol. Cell Biol. (2000) 20:6095–6104.
  • REYES H, REISZ-PORSZASZ S, HANKINSON O: Identification of the Ah receptor nuclear translocator protein (Arnt) as a component of the DNA binding form of the Ah receptor. Science (1992) 256:1193–1195.
  • KOLLURI SK, BALDUF C, HOFMANN M, GOTTLICHER M: Novel target genes of the Ah (dioxin) receptor: transcriptional induction of N-myristoyltransferase 2. Cancer Res. (2001) 61:8534–8539.
  • KOLLURI SK, WEISS C, KOFF A, GOTTLICHER M: p27(Kip1) induction and inhibition of proliferation by the intracellular Ah receptor in developing thymus and hepatoma cells. Genes Dev. (1999) 13:1742–1753.
  • SOGAWA K, NUMAYAMA-TSURUTA K, TAKAHASHI T et al.: A novel induction mechanism of the rat CYP1A2 gene mediated by Ah receptor- Arnt heterodimer. Biochem. Biophys. Res. Commun. (2004) 318:746–755.
  • BOUTROS PC, MOFFAT ID, FRANC MA et al. : Dioxin-responsive AHRE-II gene battery: identification by phylogenetic footprinting. Biochem. Biophys. Res. Commun. (2004) 321:707–715.
  • BARNES-ELLERBE S, KNUDSEN KE, PUGA A: 2,3,7,8-Tetrachlorodibenzo-pdioxin blocks androgen-dependent cell proliferation of LNCaP cells through modulation of pRB phosphorylation. Mol. Pharmacol. (2004) 66:502–511.
  • MORROW D, QIN C, SMITH R 3rd, SAFE S: Aryl hydrocarbon receptormediated inhibition of LNCaP prostate cancer cell growth and hormone-induced transactivation. J. Steroid Biochem. Mol. Biol. (2004) 88:27–36.
  • PUGA A, XIA Y, ELFERINK C: Role of the aryl hydrocarbon receptor in cell cycle regulation. Chem. Biol. Interact. (2002) 141:117–130.
  • KIM DW, GAZOURIAN L, QUADRI SA, ROMIEU-MOUREZ R, SHERR DH, SONENSHEIN GE: The RelA NF-kappaB subunit and the aryl hydrocarbon receptor (AhR) cooperate to transactivate the c-myc promoter in mammary cells. Oncogene (2000) 19:5498–5506.
  • HELLSTROM PM, VITOLS S: The choice of proton pump inhibitor: does it matter? Basic Clin. Pharmacol. Toxicol. (2004) 94:106–111.
  • BACKLUND M, JOHANSSON I, MKRTCHIAN S, INGELMAN-SUNDBERG M: Signal transduction-mediated activation of the aryl hydrocarbon receptor in rat hepatoma H4IIE cells. J. Biol. Chem. (1997) 272:31755–31763.
  • DZELETOVIC N, MCGUIRE J, DAUJAT M et al.: Regulation of dioxin receptor function by omeprazole. J. Biol. Chem. (1997) 272:12705–12713.
  • EMA M, OHE N, SUZUKI M et al.: Dioxin binding activities of polymorphic forms of mouse and human arylhydrocarbon receptors. J. Biol. Chem. (1994) 269:27337–27343.
  • RAMADOSS P, PERDEW GH: Use of 2-azido-3-[125I]iodo-7,8-dibromodibenzop- dioxin as a probe to determine the relative ligand affinity of human versus mouse aryl hydrocarbon receptor in cultured cells. Mol. Pharmacol. (2004) 66:129–136.
  • BACKLUND M, INGELMAN-SUNDBERG M: Different structural requirements of the ligand binding domain of the aryl hydrocarbon receptor for high- and low-affinity ligand binding and receptor activation. Mol. Pharmacol. (2004) 65:416–425.
  • AIX L, REY-GROBELLET X, LARRIEU G, LESCA P, GALTIER P: Thiabendazole is an inducer of cytochrome P4501A1 in cultured rabbit hepatocytes. Biochem. Biophys. Res. Commun. (1994) 202:1483–1489.
  • KIKUCHI H, KATO H, MIZUNO M et al.: Differences in inducibility of CYP1A1-mRNA by benzimidazole compounds between human and mouse cells: evidences of a human-specific signal transduction pathway for CYP1A1 induction. Arch. Biochem. Biophys. (1996) 334:235–340.
  • HOLCOMB M, SAFE S: Inhibition of 7,12-dimethylbenzanthracene-induced rat mammary tumor growth by 2,3,7,8- tetrachlorodibenzo-p-dioxin. Cancer Lett. (1994) 82:43–47.
  • MCDOUGAL A, WILSON C, SAFE S: Inhibition of 7,12- dimethylbenz[a]anthracene-induced rat mammary tumor growth by aryl hydrocarbon receptor agonists. Cancer Lett. (1997) 120:53–63.
  • MCDOUGAL A, WORMKE M, CALVIN J, SAFE S: Tamoxifen-induced antitumorigenic/antiestrogenic action synergized by a selective aryl hydrocarbon receptor modulator. Cancer Res. (2001) 61:3902–3907.
  • MCDOUGAL A, GUPTA MS, MORROW D, RAMAMOORTHY K, LEE JE, SAFE SH: Methyl-substituted diindolylmethanes as inhibitors of estrogeninduced growth of T47D cells and mammary tumors in rats. Breast Cancer Res. Treat. (2001) 66:147–157.
  • RAHMAN KM, ARANHA O, SARKAR FH: Indole-3-carbinol (I3C) induces apoptosis in tumorigenic but not in nontumorigenic breast epithelial cells. Nutr. Cancer (2003) 45:101–112.
  • NACHSHON-KEDMI M, YANNAI S, HAJ A, FARES FA: Indole-3-carbinol and 3,3’-diindolylmethane induce apoptosis in human prostate cancer cells. Food Chem. Toxicol. (2003) 41:745–752.
  • COVER CM, HSIEH SJ, TRAN SH et al. : Indole-3-carbinol inhibits the expression of cyclin-dependent kinase-6 and induces a G1 cell cycle arrest of human breast cancer cells independent of estrogen receptor signaling. J. Biol. Chem. (1998) 273:3838–3847.
  • ZHANG J, HSU BAJ, KINSETH BAM, BJELDANES LF, FIRESTONE GL: Indole-3-carbinol induces a G1 cell cycle arrest and inhibits prostate-specific antigen production in human LNCaP prostate carcinoma cells. Cancer (2003) 98:2511–2520.
  • WORMKE M, STONER M, SAVILLE B et al.: The aryl hydrocarbon receptor mediates degradation of estrogen receptor alpha through activation of proteasomes. Mol. Cell Biol. (2003) 23:1843–1855.
  • ROGERS JM, DENISON MS: Analysis of the antiestrogenic activity of 2,3,7,8- tetrachlorodibenzo-p-dioxin in human ovarian carcinoma BG-1 cells. Mol. Pharmacol. (2002) 61:1393–1403.
  • KRISHNAN V, PORTER W, SANTOSTEFANO M, WANG X, SAFE S: Molecular mechanism of inhibition of estrogen-induced cathepsin D gene expression by 2,3,7,8-tetrachlorodibenzo-pdioxin (TCDD) in MCF-7 cells. Mol. Cell Biol. (1995) 15:6710–6719.
  • GILLESBY BE, STANOSTEFANO M, PORTER W, SAFE S, WU ZF, ZACHAREWSKI TR: Identification of a motif within the 5’ regulatory region of pS2 which is responsible for AP-1 binding and TCDD-mediated suppression. Biochemistry (1997) 36:6080–6089.
  • OHTAKE F, TAKEYAMA K, MATSUMOTO T et al.: Modulation of oestrogen receptor signalling by association with the activated dioxin receptor. Nature (2003) 423:545–550.
  • CAUCHI S, STUCKER I, SOLAS C et al.: Polymorphisms of human aryl hydrocarbon receptor (AhR) gene in a French population: relationship with CYP1A1 inducibility and lung cancer. Carcinogenesis (2001) 22:1819–1824.
  • KAWAJIRI K, WATANABE J, EGUCHI H, NAKACHI K, KIYOHARA C, HAYASHI S: Polymorphisms of human Ah receptor gene are not involved in lung cancer. Pharmacogenetics (1995) 5:151–158.
  • SMART J, DALY AK: Variation in induced CYP1A1 levels: relationship to CYP1A1, Ah receptor and GSTM1 polymorphisms. Pharmacogenetics (2000) 10:11–24.
  • HARPER PA, WONG JY, LAM MS, OKEY AB: Polymorphisms in the human AH receptor. Chem. Biol. Interact. (2002) 141:161–187.
  • BERWICK M, MATULLO G, SONG YS et al. : Association between aryl hydrocarbon receptor genotype and survival in soft tissue sarcoma. J. Clin. Oncol. (2004) 22:3997–4001.
  • WONG JM, OKEY AB, HARPER PA: Human aryl hydrocarbon receptor polymorphisms that result in loss of CYP1A1 induction. Biochem. Biophys. Res. Commun. (2001) 288:990–996.
  • POLAND A, GLOVER E: Characterization and strain distribution pattern of the murine Ah receptor specified by the Ahd and Ahb-3 alleles. Mol. Pharmacol. (1990) 38:306–312.
  • POHJANVIRTA R, WONG JM, LI W, HARPER PA, TUOMISTO J, OKEY AB: Point mutation in intron sequence causes altered carboxyl-terminal structure in the aryl hydrocarbon receptor of the most 2,3,7,8- tetrachlorodibenzo-p-dioxinresistant rat strain. Mol. Pharmacol. (1998) 54:86–93.
  • KORKALAINEN M, TUOMISTO J, POHJANVIRTA R: Restructured transactivation domain in hamster AH receptor. Biochem. Biophys. Res. Commun. (2000) 273:272–281.
  • RAMADOSS P, PETRULIS JR, HOLLINGSHEAD BD, KUSNADI A, PERDEW GH: Divergent roles of hepatitis B virus X-associated protein 2 (XAP2) in human versus mouse Ah receptor complexes. Biochemistry (2004) 43:700–709.
  • MORIGUCHI T, MOTOHASHI H, HOSOYA T et al.: Distinct response to dioxin in an arylhydrocarbon receptor (AHR)-humanized mouse. Proc. Natl Acad. Sci. USA (2003) 100:5652–5657.
  • DING X, KAMINSKY LS: Human extrahepatic cytochromes P450: function in xenobiotic metabolism and tissue-selective chemical toxicity in the respiratory and gastrointestinal tracts. Ann. Rev. Pharmacol. Toxicol. (2003) 43:149–173.
  • HASLER JA: Pharmacogenetics of cytochromes P450. Mol. Aspects Med. (1999) 20:12–24, 25–137.
  • SUN YV, BOVERHOF DR, BURGOON LD, FIELDEN MR, ZACHAREWSKI TR: Comparative analysis of dioxin response elements in human, mouse and rat genomic sequences. Nucleic Acids Res. (2004) 32:4512–4523.
  • SPINK DC, HAYES CL, YOUNG NR et al. : The effects of 2,3,7,8- tetrachlorodibenzo-p-dioxin on estrogen metabolism in MCF-7 breast cancer cells: evidence for induction of a novel 17 betaestradiol 4-hydroxylase. J. Steroid Biochem. Mol. Biol. (1994) 51:251–258.
  • CHEN H, HOWALD WN, JUCHAU MR: Biosynthesis of all-transretinoic acid from all-trans-retinol: catalysis of all-trans-retinol oxidation by human P450 cytochromes. Drug Metab. Dispos. (2000) 28:315–322.
  • CHOUDHARY D, JANSSON I, STOILOV I, SARFARAZI M, SCHENKMAN JB: Metabolism of retinoids and arachidonic acid by human and mouse cytochrome P450 1b1. Drug Metab. Dispos. (2004) 32:840–847.
  • ZHANG QY, DUNBAR D, KAMINSKY L: Human cytochrome P450 metabolism of retinals to retinoic acids. Drug Metab. Dispos. (2000) 28:292–297.
  • SINCLAIR PR, GORMAN N, WALTON HS et al. : CYP1A2 is essential in murine uroporphyria caused by hexachlorobenzene and iron. Toxicol. Appl. Pharmacol. (2000) 162:60–67.
  • SHIMADA T, FUJII-KURIYAMA Y: Metabolic activation of polycyclic aromatic hydrocarbons to carcinogens by cytochromes P450 1A1 and 1B1. Cancer Sci. (2004) 95:1–6.
  • DALY AK: Pharmacogenetics of the major polymorphic metabolizing enzymes. Fundam. Clin. Pharmacol. (2003) 17:27–41.
  • GRANVIL CP, KRAUSZ KW, GELBOIN HV, IDLE JR, GONZALEZ FJ: 4-Hydroxylation of debrisoquine by human CYP1A1 and its inhibition by quinidine and quinine. J. Pharmacol. Exp. Ther. (2002) 301:1025–1032.
  • CHUA MS, KASHIYAMA E, BRADSHAW TD et al. : Role of CYP1A1 in modulation of antitumor properties of the novel agent 2–(4-amino-3- methylphenyl)benzothiazole (DF 203, NSC 674495) in human breast cancer cells. Cancer Res. (2000) 60:5196–5203.
  • LOAIZA-PEREZ AI, TRAPANI V, HOSE C et al.: Aryl hydrocarbon receptor mediates sensitivity of MCF-7 breast cancer cells to antitumor agent 2–(4-amino-3- methylphenyl) benzothiazole. Mol. Pharmacol. (2002) 61:13–19.
  • MACDONALD CJ, CIOLINO HP, YEH GC: The drug salicylamide is an antagonist of the aryl hydrocarbon receptor that inhibits signal transduction induced by 2,3,7,8-tetrachlorodibenzo-p-dioxin. Cancer Res. (2004) 64:429–434.
  • SHIMADA T, GILLAM EM, SUTTER TR, STRICKLAND PT, GUENGERICH FP, YAMAZAKI H: Oxidation of xenobiotics by recombinant human cytochrome P450 1B1. Drug Metab. Dispos. (1997) 25:617–622.
  • MURRAY GI, MELVIN WT, GREENLEEWF, BURKE MD: Regulation, function, and tissue-specific expression of cytochrome P450 CYP1B1. Ann. Rev. Pharmacol. Toxicol. (2001) 41:297–316.
  • JOHNSON CD, BALAGURUNATHAN Y, TADESSE MG et al. : Unraveling gene-gene interactions regulated by ligands of the aryl hydrocarbon receptor. Environ. Health Perspect. (2004) 112:403–412.
  • MCFADYEN MC, MELVIN WT, MURRAY GI: Cytochrome P450 CYP1B1 activity in renal cell carcinoma. Br. J. Cancer (2004) 91:966–971.
  • MURRAY GI, TAYLOR MC, MCFADYEN MC et al. : Tumor-specific expression of cytochrome P450 CYP1B1. Cancer Res. (1997) 57:3026–3031.
  • TANAKA Y, SASAKI M, KANEUCHI M, SHIINA H, IGAWA M, DAHIYA R: Polymorphisms of the CYP1B1 gene have higher risk for prostate cancer. Biochem. Biophys. Res. Commun. (2002) 296:820–826.
  • BUTERS JT, SAKAI S, RICHTER T et al.: Cytochrome P450 CYP1B1 determines susceptibility to 7, 12- dimethylbenz[a]anthracene-induced lymphomas. Proc. Natl Acad. Sci. USA (1999) 96:1977–1982.
  • HAKKOLA J, PASANEN M, PELKONEN O et al.: Expression of CYP1B1 in human adult and fetal tissues and differential inducibility of CYP1B1 and CYP1A1 by Ah receptor ligands in human placenta and cultured cells. Carcinogenesis (1997) 18:391–397.
  • LEE AJ, CAI MX, THOMAS PE, CONNEY AH, ZHU BT: Characterization of the oxidative metabolites of 17betaestradiol and estrone formed by 15 selectively expressed human cytochrome P450 isoforms. Endocrinology (2003) 144:3382–3398.
  • TSUCHIYA Y, NAKAJIMA M, KYO S, KANAYA T, INOUE M, YOKOI T: Human CYP1B1 is regulated by estradiol via estrogen receptor. Cancer Res. (2004) 64:3119–3125.
  • TAKEMOTO K, NAKAJIMA M, FUJIKI Y, KATOH M, GONZALEZ FJ, YOKOI T: Role of the aryl hydrocarbon receptor and Cyp1b1 in the antiestrogenic activity of 2,3,7,8-tetrachlorodibenzo-pdioxin. Arch. Toxicol. (2004) 78:309–315.
  • LIBBY RT, SMITH RS, SAVINOVA OV et al. : Modification of ocular defects in mouse developmental glaucoma models by tyrosinase. Science (2003) 299:1578–1581.
  • STOILOV I, AKARSU AN, SARFARAZI M: Identification of three different truncating mutations in cytochrome P4501B1 (CYP1B1) as the principal cause of primary congenital glaucoma (Buphthalmos) in families linked to the GLC3A locus on chromosome 2p21. Hum. Mol. Genet. (1997) 6:641–647.
  • DALY AK: Pharmacogenetics of the cytochromes P450. Curr. Top. Med. Chem. (2004) 4:1733–1744.
  • INGELMAN-SUNDBERG M: Human drug metabolising cytochrome P450 enzymes: properties and polymorphisms. Naunyn Schmiedebergs Arch. Pharmacol. (2004) 369:89–104.
  • AKLILLU E, OSCARSON M, HIDESTRAND M, LEIDVIK B, OTTER C, INGELMAN-SUNDBERG M: Functional analysis of six different polymorphic CYP1B1 enzyme variants found in an Ethiopian population. Mol. Pharmacol. (2002) 61:586–594.
  • BEJJANI BA, XU L, ARMSTRONG D, LUPSKI JR, RENEKER LW: Expression patterns of cytochrome P4501B1 (Cyp1b1) in FVB/N mouse eyes. Exp. Eye Res. (2002) 75:249–257.
  • CHOUDHARY D, JANSSON I, SCHENKMAN JB, SARFARAZI M, STOILOV I: Comparative expression profiling of 40 mouse cytochrome P450 genes in embryonic and adult tissues. Arch. Biochem. Biophys. (2003) 414:91–100.
  • STOILOV I, REZAIE T, JANSSON I, SCHENKMAN JB, SARFARAZI M: Expression of cytochrome P4501b1 (CYP1B1) during early murine development. Mol. Vis. (2004) 10:629–636.
  • KIM JS, LIM HS, CHO SI, CHEONG HK, LIM MK: Impact of agent orange exposure among Korean Vietnam veterans. Ind. Health (2003) 41:149–157.
  • VONDRACEK M, WEAVER DA, SARANG Z et al.: Transcript profiling of enzymes involved in detoxification of xenobiotics and reactive oxygen in human normal and simian virus 40 T antigenimmortalized oral keratinocytes. Int. J. Cancer (2002) 99:776–782.
  • CHANG BL, ZHENG SL, ISAACS SD et al. : Polymorphisms in the CYP1B1 gene are associated with increased risk of prostate cancer. Br. J. Cancer (2003) 89:1524–1529.
  • RAGAVAN N, HEWITT R, COOPER LJ et al. : CYP1B1 expression in prostate is higher in the peripheral than in the transition zone. Cancer Lett. (2004) 215:69–78.
  • SASAKI M, TANAKA Y, KANEUCHI M, SAKURAGI N, DAHIYA R: CYP1B1 gene polymorphisms have higher risk for endometrial cancer, and positive correlations with estrogen receptor alpha and estrogen receptor beta expressions. Cancer Res. (2003) 63:3913–3918.
  • MCFADYEN MC, MELVIN WT, MURRAY GI: Cytochrome P450 enzymes: novel options for cancer therapeutics. Mol. Cancer Ther. (2004) 3:363–371.
  • ROCHAT B, MORSMAN JM, MURRAY GI, FIGG WD, MCLEOD HL: Human CYP1B1 and anticancer agent metabolism: mechanism for tumor-specific drug inactivation? J. Pharmacol. Exp. Ther. (2001) 296:537–541.
  • BOURNIQUE B, LEMARIE A: Docetaxel (Taxotere) is not metabolized by recombinant human CYP1B1 in vitro, but acts as an effector of this isozyme. Drug Metab. Dispos. (2002) 30:1149–1152.
  • MCFADYEN MC, MCLEOD HL, JACKSON FC, MELVIN WT, DOEHMER J, MURRAY GI: Cytochrome P450 CYP1B1 protein expression: a novel mechanism of anticancer drug resistance. Biochem. Pharmacol. (2001) 62:207–212.
  • CREWE HK, NOTLEY LM, WUNSCH RM, LENNARD MS, GILLAM EM: Metabolism of tamoxifen by recombinant human cytochrome P450 enzymes: formation of the 4-hydroxy, 4’- hydroxy and N-desmethyl metabolites and isomerization of trans-4-hydroxytamoxifen. Drug Metab. Dispos. (2002) 30:869–874.
  • CHUN YJ, KIM S: Discovery of cytochrome P450 1B1 inhibitors as new promising anti-cancer agents. Med. Res. Rev. (2003) 23:657–668.
  • HOSE CD, HOLLINGSHEAD M, SAUSVILLE EA, MONKS A: Induction of CYP1A1 in tumor cells by the antitumor agent 2-[4-amino-3-methylphenyl]-5- fluoro-benzothiazole: a potential surrogate marker for patient sensitivity. Mol. Cancer Ther. (2003) 2:1265–1272.
  • POTTER GA, PATTERSON LH, WANOGHO E et al.: The cancer preventative agent resveratrol is converted to the anticancer agent piceatannol by the cytochrome P450 enzyme CYP1B1. Br. J. Cancer (2002) 86:774–778.
  • COZZA KL, ARMSTRONG SC: P450 Enzymes: 1A2. In: Concise guide to the cytochrome P450 system drug interaction principles for medical practice. RE Hales (Ed.), American Psychiatric Publishing, Inc., USA (2001):69–78.
  • NAKAJIMA M, YOKOI T, MIZUTANI M, KINOSHITA M, FUNAYAMA M, KAMATAKI T: Genetic polymorphism in the 5’- flanking region of human CYP1A2 gene: effect on the CYP1A2 inducibility in humans. J. Biochem. (1999) 125:803–808.
  • SACHSE C, BROCKMOLLER J, BAUER S, ROOTS I: Functional significance of a C- > A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. Br. J. Clin. Pharmacol. (1999) 47:445–449.
  • RIVERA SP, SAARIKOSKI ST, HANKINSON O: Identification of a novel dioxin-inducible cytochrome P450. Mol. Pharmacol. (2002) 61:255–259.
  • RYLANDER T, NEVE EP, INGELMAN-SUNDBERG M, OSCARSON M: Identification and tissue distribution of the novel human cytochrome P450 2S1 (CYP2S1). Biochem. Biophys. Res. Commun. (2001) 281:529–535.
  • SAARIKOSKI ST, SUITIALA T, HOLMILA R et al.: Identification of genetic polymorphisms of CYP2S1 in a Finnish Caucasian population. Mutat. Res. (2004) 554:267–277.
  • SMITH G, WOLF CR, DEENI YY et al. : Cutaneous expression of cytochrome P450 CYP2S1: individuality in regulation by therapeutic agents for psoriasis and other skin diseases. Lancet (2003) 361:1336–1343.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.